Our 24/7 Wall St. price target for Pfizer (NYSE:PFE | PFE Price Prediction) points to $32.36 over the next 12 months, implying 15.27% upside from the recent close of $28.07. Our recommendation is buy, with high model confidence of 90%. Pipeline momentum, a re-rated 2026 guide, and a 6.19% dividend yield tip the scale toward a rebound thesis.
| Metric | Value |
|---|---|
| Current Price | $28.07 |
| 24/7 Wall St. Price Target | $32.36 |
| Upside | 15.27% |
| Recommendation | BUY |
| Confidence Level | 90% |
A Quiet Rebound Is Already Underway
Pfizer has quietly become one of healthcare’s better price stories in 2026. Shares are up 18.58% year to date and 15.08% over the past month, closing at $28.07, essentially at the 52-week high of $28.44.
Q2 2026, reported August 4, delivered $15 billion in revenue, adjusted diluted EPS of 77 cents, and a raised revenue guide of $60.5 to $62.5 billion, even with a $4.3 billion writedown stealing headlines. CEO Albert Bourla noted this was the “ninth time we exceeded consensus expectations for revenues in the last ten quarters.”
Why Bulls See a Breakout Ahead
The bull case rests on execution. Launched and acquired products grew 22% operationally in Q1 2026, with Padcev up 39% and Nurtec ODT/Vydura up 42%. Pfizer expects 19 pivotal study starts over the next 12 months across oncology, obesity, and immunology.
Management is guiding to a high single-digit revenue CAGR from year end 2028 through 2033. If the obesity pipeline hits, our bull-case model reaches $36.17 within a year, and $52.18 over five.
Risks Worth Watching Now
The bear case starts with COVID: Comirnaty fell 59% and Paxlovid 62% in Q1 2026. Generic and biosimilar competition will drag roughly $1.5 billion off 2026 revenue, and no buybacks are planned despite a $3.3 billion authorization.
Q1 operating income fell 31.44% year over year, though bulls would argue that reflects heavy R&D reinvestment ($5.5 billion deployed in the first half of 2026) that funds the post-2028 growth ramp. Our bear-case path bottoms near $28.60.
How Pfizer Compares to Merck and Bristol Myers Squibb
Merck (NYSE:MRK) is the closest big-pharma peer on oncology and vaccines, anchored by KEYTRUDA, which posted $8.03 billion in Q1 2026 sales, up 12%. Merck guides 2026 non-GAAP EPS of $5.04 to $5.16 (absorbing a Cidara charge). Ex-charge, Merck trades near 18x forward earnings versus Pfizer at 10x. That valuation gap is the entire reason Pfizer looks like the rebound trade.
Bristol Myers Squibb (NYSE:BMY) shares Pfizer’s patent-cliff narrative and co-markets Eliquis. BMS guides 2026 non-GAAP EPS of $6.05 to $6.35, putting it near 11x forward earnings. Bristol Myers is priced for a similar rebound story to Pfizer, which supports the view that our 24/7 Wall St. price target is reasonable.
Pfizer Price Prediction 2026-2030
Our 24/7 Wall St. price target of $32.36 and buy rating carry 90% confidence. The single factor that tips the scale is the combination of a 6.19% dividend yield with a genuine pipeline reacceleration.
The bullish setup strengthens if oncology and obesity readouts continue to land and COVID declines stabilize near management’s $4 billion guide. The thesis weakens if Paxlovid disappoints again or the Metsera obesity data underwhelm in 2027.
| Year | 24/7 Wall St. Price Target |
|---|---|
| 2026 | $32 |
| 2027 | $35 |
| 2028 | $38 |
| 2029 | $41 |
| 2030 | $45 |
These projections extend our base-case CAGR of 9.7% and assume Pfizer executes on its 2028+ growth reacceleration. Significant upside or downside could come from obesity approvals, Vyndamax post-2031 competition, or Section 232 pharmaceutical tariffs.
Contact [email protected] for any questions or corrections.
Top Gaining Stocks
Top Losing Stocks